Key Drivers
- Revenue Collapse
- Rising Leverage
- Cash Burn
AIAI Summary
ARWR is now a commercial-execution story: SHASTA strengthens plozasiran's severe-hypertriglyceridemia expansion potential, but investors should require evidence of a timely filing, broad label, reimbursement, and accelerating sales before overlooking heavy cash burn and leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Revenue Collapse
- •Rising Leverage
- •Cash Burn
ARWR's revenue collapse, steep losses, negative cash flow, and rising leverage materially weaken its investment outlook despite investment-backed liquidity.
Price Behavior
Key Price Behavior Insights:
- •Sharp monthly decline
- •Oversold rebound attempt
- •Key support test
ARWR remains bearish over the last month, with oversold momentum hinting at a possible bounce, but a break below $65.79 would increase downside risk unless it reclaims $70.67.
Sharp drop from $80.67 to $65.79 in two trading days
Sentiment & News
Key News Insights:
- •Phase 3 success
- •Pipeline expansion
- •Institutional buying
Arrowhead's positive Phase 3 plozasiran results and early ARO-DIMER-PA data strengthen its cardiovascular pipeline outlook despite insider selling.
Strong clinical momentum could support investor sentiment and valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings